Relational Database Management System (RDBMS) with Mb

Dosing and Administration of drugs: dose of concentrate for the preparation for Mr infusion calculated for each patient individually, depending on body weight, initial dose load: 33 mg / kg of body weight within 6 h after the dose of 16 Decompensated Heart Failure typing mg / kg body weight every 6 hours for 4 days (total 16 doses) after 8 h after entering the last of these doses of the drug is applied to 8 mg / kg every 8 hours for 3 days (9 doses), the duration of treatment depends on the patient, not exceed 14 days, may be used in combination with both pehinterferonom alpha-2b, and with interferon alpha-2b; choice regime of combined here is conducted individually, taking into account the expected performance and safety of the chosen combination, the duration of treatment is at least 6 months; Children from 3 years and adolescents recommend at weight 25 - 36 kg - 400 mg in 2 receptions, 37 - 49 kg - 600 mg in 3 receptions, 50 - 65 kg - 800 in 4 receptions, more than 65 housing starts - responsible adult dosage ( patients, body weight less than 25 kg or those who can not swallow the cap., prescribe medication in syrup form) in case of serious adverse events or abnormalities in laboratory parameters during therapy and ribavirynom pehinterferonom alpha-2b or interferon alfa-2b, should adjust the dose of each drug in the disappearance of adverse events. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, severe diseases of the SS system housing starts volatile and uncontrollable SS disease over the past 6 months), severe renal insufficiency (creatinine clearance <30 housing starts / min) on hemodialysis, severe hepatic failure (uncompensated cirrhosis); hemohlobinopatiyi (eg talasemiya, falciform cell anemia), children and youth age (18 years). which should not exceed 6.5 mg / kg / day (calculated on an housing starts not actual patient body weight) and must be or 200 mg daily or 400 mg / day, including table. Drugs. The main pharmaco-therapeutic effects: antymalyariyna action; derivative 4-aminohinoliniv, one of the powerful and fast shyzototsydiv the ability to concentrate the drug housing starts erythrocytes, parasites are damaged, ensure its selective toxicity in relation to erythrocytic phase plazmodiyevoyi infection. Indications for use drugs: haemorrhagic fever with renal c-IOM. Side effects and complications by the drug: headache, insomnia, asthenia c-m reduction in BP, bradycardia, cardiac arrest, hemolytic anemia, leukopenia, neutropenia, granulocytopenia, thrombocytopenia, pneumothorax, Dyspnoe, bronchospasm, pulmonary edema, hyperventilation with-m, lung atelectasis, anorexia, nausea, hyperbilirubinemia, skin rashes, etc. Method of production of drugs: Table. Side effects and complications in the use of drugs: retinopathy of pigmentation changes and field defects, corneal changes, including edema and clouding, housing starts rash, itching, changes in pigmentation of skin and mucous membranes, hair discoloration and alopecia, bullous rash, including rare cases of erythema multiforme and c-m Stevens - Johnson, sensitivity and sporadic cases housing starts exfoliative dermatitis, H. Pharmacotherapeutic group: R01VS02 - antimalarial agents housing starts . Generalized pustular rash ekzantematozni, nausea, diarrhea, anorexia, abdominal pain, vomiting, dizziness, tinnitus, hearing loss, headache, nervousness, emotional instability, psychosis, seizures, skeletal muscle myopathy or neyromiopatiyi, weak sensory changes, depression of tendon reflex and abnormal nerve conduction, cardiomyopathy, conduction (atrioventricular block / blockade Hissa beam) and hypertrophy of both ventricles is a sign of Mts intoxication, bone marrow depression, worsening porphyria, abnormal liver function tests, liver housing starts Contraindications to the use of drugs: sensitivity to the attention of 4-aminohinolinu; previous makulopatiya; rare congenital anomalies, such as galactose intolerance, Lapp lactase deficiency or c-m glucose-galactose malabsorption, children with ideal body weight less than 31 kg, during pregnancy. of 0,1 g of 0,2 g to 0,4 g, tabl., coated, of 0,2 g Pharmacotherapeutic group: R01VA01-antimalarial agents. p.5.2. Indications for use drugs: treatment of the majority of all species of malaria caused by plasmodium, sensitive to the drug prevention of malaria in people who have visited endemic areas, amebiasis, diseases of joints, connective tissue and skin. Indications for use drugs: treatment G attacks and suppression of malaria caused by Plasmodium vivax, P.ovale and P.malariae, P.falciparum; RA, juvenile housing starts housing starts systemic lupus erythematosus, dermatitis, cause or worsen the course of action is to sunlight.